Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aegerion Pharma Inc (AEGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 55,250
  • Shares Outstanding, K 29,540
  • Annual Sales, $ 239,890 K
  • Annual Income, $ -73,340 K
  • 36-Month Beta 0.50
  • Price/Sales 0.23
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.07
  • Most Recent Earnings -0.37 on 11/03/16
  • Next Earnings Date 11/14/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +31.33%
on 11/07/16
2.34 -15.81%
on 11/29/16
+0.14 (+7.65%)
since 10/28/16
3-Month
1.50 +31.33%
on 11/07/16
3.35 -41.19%
on 09/29/16
+0.33 (+20.12%)
since 08/29/16
52-Week
1.23 +60.16%
on 06/14/16
10.85 -81.84%
on 12/24/15
-8.49 (-81.17%)
since 11/27/15

Most Recent Stories

More News
Novelion Therapeutics' Subsidiary Launches JUXTAPID(R) (lomitapide) in Japan

Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first commercial shipment of JUXTAPID(R) (lomitapide) to a patient in Japan. In September...

AEGR : 1.97 (+5.35%)
NVLN.TO : 13.30 (-2.56%)
NVLN : 8.86 (-3.17%)
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)

-- Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide -

AEGR : 1.97 (+5.35%)
NVLN.TO : 13.30 (-2.56%)
NVLN : 8.86 (-3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat lipid disorders. Its products include Lomitapide and Implitapide. Lomitapide is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, that is...

See More

Support & Resistance

2nd Resistance Point 2.54
1st Resistance Point 2.25
Last Price 1.97
1st Support Level 1.77
2nd Support Level 1.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.